The authors wrote the first draft of the manuscript (James F. Trotter wrote the introduction and the section titled Avoiding or Limiting the Use of Calcineurin Inhibitors in the Maintenance Phase; Monica Grafals wrote the section titled Renal Dysfunction in Liver Transplant Candidates and Recipients, and Angel E. Alsina wrote the section titled Calcineurin Inhibitor Avoidance in the Induction Period). The authors' contributions were merged together by Danita Sutton, Ph.D. (Oxford PharmaGenesis, Inc.), who provided editorial assistance to improve the flow and eliminate any redundancies. Sutton also provided assistance with figure preparation and styling of the manuscript for submission. The final draft was approved by all the authors.
Early use of renal-sparing agents in liver transplantation: A closer look
Article first published online: 29 JUL 2013
© 2013 American Association for the Study of Liver Diseases
Volume 19, Issue 8, pages 826–842, August 2013
How to Cite
Trotter, J. F., Grafals, M. and Alsina, A. E. (2013), Early use of renal-sparing agents in liver transplantation: A closer look. Liver Transpl, 19: 826–842. doi: 10.1002/lt.23672
Funding for editorial assistance from Oxford PharmaGenesis, Inc., was provided by Novartis Pharmaceuticals Corp. The authors are fully responsible for all content and editorial decisions, and they received no financial support or other form of compensation related to the development of this article. The opinions expressed in this article are those of the authors, and Novartis Pharmaceuticals had no influence on the contents.
James F. Trotter is part of the speakers' bureau for Novartis and Salix and has advisory arrangements with Novartis. Monica Grafals has nothing to disclose. Angel E. Alsina is part of the speakers' bureau for Bayer and Novartis and has advisory arrangements with Bayer and Onyx.
- Issue published online: 29 JUL 2013
- Article first published online: 29 JUL 2013
- Accepted manuscript online: 21 MAY 2013 03:55AM EST
- Manuscript Accepted: 28 APR 2013
- Manuscript Received: 12 DEC 2012
- 1Organ Procurement and Transplantation Network (OPTN) and Scientific Registry of Transplant Recipients (SRTR). OPTN/SRTR 2010 Annual Data Report. Rockville, MD: Department of Health and Human Services, Health Resources and Services Administration, Healthcare Systems Bureau, Division of Transplantation; 2011.
- 13for International Liver Transplantation Society Expert Panel. Report of the first International Liver Transplantation Society expert panel consensus conference on renal insufficiency in liver transplantation. Liver Transpl 2009;15:S1-S34., , , , , , et al.;
- 24Evaluation of renal function in liver transplant recipients receiving daclizumab (Zenapax), mycophenolate mofetil, and a delayed, low-dose tacrolimus regimen vs. a standard-dose tacrolimus and mycophenolate mofetil regimen: a multicenter randomized clinical trial. Liver Transpl 2005;11:1064-1072., , , , , , et al.
- 34ClinicalTrials.gov. Liver Spare the Nephron (STN) Study—a study of CellCept (mycophenolate mofetil) and sirolimus in recipients of a liver transplant. http://www.clinicaltrials.gov/ct2/show/NCT00118742. Accessed April 2013.
- 35for Sirolimus Liver Conversion Trial Study Group. Sirolimus conversion regimen versus continued calcineurin inhibitors in liver allograft recipients: a randomized trial. Am J Transplant 2012;12:694-705., , , , , , et al.;
- 37Roche Trials Database. Clinical trial result information. http://www.roche-trials.com/studyResultGet.action?studyResultNumber=ML18423. Accessed April 2013.
- 39Rapamune (Sirolimus) Oral Solution and Tablets [prescribing information]. Philadelphia, PA: Wyeth Pharmaceuticals; 2011.